HHS: Cost-sharing subsidies in ACA will be funded

Subsidies to health insurers offered under the Affordable Care Act (ACA) will continue to be funded, HHS told the New York Times, even though House Republicans had made the argument in court the payments were illegal.

The cost-sharing reduction subsidies, or CSRs, compensate insurers for reducing deductibles and out-of-pocket maximums for low-income customers on the ACA exchanges. In 2017, more than seven million people qualified for them, according to the Kaiser Family Foundation.

Those subsidies could be pulled, however, thanks to a lawsuit filed by the House of Representatives against HHS during the Obama administration. The suit argued the payments to insurers were illegal because Congress never appropriated the money. A district court judge ruled in favor of the House, but the case has been put on pause while the Trump administration decides whether to defend the Obama-era subsidies.

HHS told the Times it will continue paying out the subsidies to insurers.

“The precedent is that while the lawsuit is being litigated, the cost-sharing subsidies will be funded. It would be fair for you to report that there has been no policy change in the current administration,” the agency said in a statement.

The move may offer some assurance to skittish insurers contemplating whether to exit the exchanges, which are now being run by an administration that wants to repeal the ACA and has allies who claim the markets are in a death spiral.

Read the full article below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.